Eli Lilly and Co
LLY
Eli Lilly and Co News & Analysis
stocks
Eli Lilly earnings: Mounjaro/Zepbound’s massive volume growth more than counters price pressure
We’ve raised our fair value estimate of Lilly stock.
stocks
A wave of US biotech IPOs may be starting - here’s why
M&A activity is bolstering IPOs within key areas of the biotech space. A GLP-1 maker and a protein biomarker detection company are the latest.
stocks
Eli Lilly receives FDA approval to add another oral GLP-1 to market
Wide moat Eli Lilly receives FDA approval for obesity pill.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,178.40 | 69.70 | 0.77% |
| CAC 40 | 8,634.03 | 124.39 | 1.46% |
| DAX 40 | 26,077.62 | 448.38 | 1.75% |
| Dow JONES (US) | 53,076.02 | 590.99 | 1.13% |
| FTSE 100 | 10,846.16 | 21.89 | -0.20% |
| HKSE | 26,009.40 | 124.97 | 0.48% |
| NASDAQ | 25,775.21 | 401.36 | 1.58% |
| Nikkei 225 | 63,754.90 | 607.12 | -0.94% |
| NZX 50 Index | 13,774.93 | 75.65 | 0.55% |
| S&P 500 | 7,572.43 | 82.71 | 1.10% |
| S&P/ASX 200 | 9,019.30 | 70.30 | 0.79% |
| SSE Composite Index | 3,809.66 | 22.60 | -0.59% |